Literature DB >> 3159018

Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor.

D A Eppstein, Y V Marsh, M van der Pas, P L Felgner, A B Schreiber.   

Abstract

Recombinant murine gamma interferon (rMuIFN-gamma) was found to bind reversibly to a specific high-affinity surface receptor on L929 cells; neither murine alpha or beta nor human gamma IFN competed for receptor binding. Encapsulation of the rMuIFN-gamma in either negatively or positively charged liposomes reduced its immediate ability to bind to this surface receptor. Disruption of liposome integrity with detergent resulted in full ability of the rMuIFN-gamma to bind to the membrane receptor. Incubation of the liposomal IFN in serum-containing medium resulted in significant leakage so that the IFN was able to bind to its surface receptor. Assessment of the biological activity of the rMuIFN-gamma preparations revealed that full antiviral activity was observed in vitro with the liposomal IFN preparations without their prior disruption by detergent. The antiviral activity observed with either free or liposomal IFN was neutralized completely by antibodies against rMuIFN-gamma. Both free and liposomal rMuIFN-gamma, in conjunction with bacterial lipopolysaccharide, were also able to activate murine peritoneal macrophages to the tumoricidal state. Again, this activity of both free and liposomal IFN could be neutralized completely by antibody. These results indicate that although rMuIFN-gamma can be effectively incorporated into liposomes, it must ultimately leak out of the liposome in order to mediate its biological effects; these effects are triggered after the IFN binds to its cell surface receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159018      PMCID: PMC397852          DOI: 10.1073/pnas.82.11.3688

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Interferon externalization by producing cell before induction of antiviral state.

Authors:  V E Vengris; B D Stollar; P M Pitha
Journal:  Virology       Date:  1975-06       Impact factor: 3.616

Review 2.  Studies of the interferon receptors.

Authors:  K C Zoon; H Arnheiter
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

3.  Evidence that types I and II interferons have different receptors.

Authors:  A A Branca; C Baglioni
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Inhibition of cationic liposomes of [3H]thymidine incorporation into DNA of L1210 cells.

Authors:  G Laurent; C Laduron; J M Ruysschaert; M Deleers
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-03

5.  In situ activation of murine macrophages by liposomes containing lymphokines.

Authors:  W E Fogler; A Raz; I J Fidler
Journal:  Cell Immunol       Date:  1980-07-15       Impact factor: 4.868

6.  Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.

Authors:  S Sone; G Poste; I J Fidler
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

7.  Altered pharmacological properties of liposome-associated human interferon-alpha.

Authors:  D A Eppstein; W E Stewart
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

8.  High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse gamma interferon and cholera toxin do not compete for the common receptor site of alpha / beta interferon.

Authors:  M Aguet; F Belardelli; B Blanchard; F Marcucci; I Gresser
Journal:  Virology       Date:  1982-03       Impact factor: 3.616

9.  Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.

Authors:  G Poste; R Kirsh; W E Fogler; I J Fidler
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

10.  Control of in vitro cytotoxicity of positively charged liposomes.

Authors:  E A Panzner; V K Jansons
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

View more
  8 in total

1.  The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes.

Authors:  S Cohen; H Bernstein; C Hewes; M Chow; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

Authors:  I Rutenfranz; A Bauer; H Kirchner
Journal:  Blut       Date:  1990-07

3.  Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-gamma and their uptake by isolated rat hepatocytes.

Authors:  H Ishihara; T Hara; Y Aramaki; S Tsuchiya; K Hosoi
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 4.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

5.  Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice.

Authors:  L Degling; P Stjärnkvist; I Sjöholm
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

6.  Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity.

Authors:  J W Mellors; R J Debs; J L Ryan
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 7.  Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control.

Authors:  Kai-Chieh Yang; Jung-Chen Lin; Hsiao-Han Tsai; Chung-Yao Hsu; Vicky Shih; Che-Ming Jack Hu
Journal:  Drug Deliv Transl Res       Date:  2021-03-21       Impact factor: 4.617

8.  A System of Cytokines Encapsulated in ExtraCellular Vesicles.

Authors:  Wendy Fitzgerald; Michael L Freeman; Michael M Lederman; Elena Vasilieva; Roberto Romero; Leonid Margolis
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.